DANBURY, CT-- Biodel Inc. (BIOD) announced positive preliminary results from Study 3-152, a Phase 2a clinical trial comparing Biodel's proprietary, concentrated insulin formulation BIOD-531 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results